NICE 'yes' to Esbriet, Xolair and Orencia
This article was originally published in Scrip
Executive Summary
In its latest round of decisions, NICE England's health technology appraisal institute, has recommended Intermune's Esbriet (pirfenidone) for certain idiopathic pulmonary fibrosis patients, Novartis' Xolair (omalizumab) as an option for severe, persistent allergic asthma as well as a wider use for Bristol-Myers Squibb's Orencia (abatacept) for rheumatoid arthritis .